Dr. Cheung Ho Kwan Alvin - Pathology
Specialist in Pathology
Highlights
- MCHK RegisteredVerified
- Specialist in PathologyBachelor of Medicine and Bachelor of Surgery (MBBS) · The Hong Kong College of Pathologists · Medical degree 2013
- InsuranceBeing compiled｜See details
About
Dr. Cheung Ho Kwan Alvin is a registered Pathology specialist in Hong Kong.
Education
Specialist in Pathology
- Bachelor of Medicine and Bachelor of Surgery (MBBS)Bachelor of Medicine and Bachelor of Surgery (MBBS)2013
Hong Kong Academy of Medicine fellowships
- FHKCPathFellow, The Hong Kong College of Pathologists
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Cheung Ho Kwan Alvin? Claim page and update insurance →
FAQ
Is Dr. Cheung Ho Kwan Alvin any good?
Dr. Cheung Ho Kwan Alvin is a registered Pathology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Cheung Ho Kwan Alvin do?
Dr. Cheung Ho Kwan Alvin practises in Pathology.
Are you Dr. Cheung Ho Kwan Alvin? Claim this page to update and manage.
ClaimResearch and publications
26 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2026
- Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy.Gut · 2025
- Targeting of the m<sup>6</sup>A eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer.Nature communications · 2025
- Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice.Nature microbiology · 2024
- SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.Pathology · 2024
- FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives Metastasis.Cancer research · 2024
- METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy.Cell reports. Medicine · 2023
- Out of the cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis.International journal of cancer · 2023
- Targeting YAP1/TAZ in nonsmall-cell lung carcinoma: From molecular mechanisms to precision medicine.International journal of cancer · 2023
- MLK4 promotes glucose metabolism in lung adenocarcinoma through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is regulated by KLF5.Oncogenesis · 2023
- Interpretation of Lung Cancer Plasma EGFR Mutation Tests in the Clinical Setting.American journal of clinical pathology · 2023
- Cancer-associated fibroblasts in nonsmall cell lung cancer: From molecular mechanisms to clinical implications.International journal of cancer · 2022
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer